Sp453
BASIL I. HIRSCHOWITZ MD ENDOWED LECTURE
Date
May 19, 2024
Presenter
Icahn School of Medicine, Mount Sinai
Tracks
Related Products
THE EFFECT OF NLRX1 ACTIVATION ON EOSINOPHILS IN ULCERATIVE COLITIS AND INFLAMMATION: TRANSLATIONAL LEARNINGS ACROSS DISEASES AND FROM MOUSE TO HUMAN
Background: Although the precise role of eosinophils in IBD is debated, elevated eosinophils may influence response to therapy and clinical outcomes1. Thus, therapeutic agents which affect both neutrophil and eosinophil recruitment may provide more robust clinical improvement in patients with UC…
EARLY ULTRASOUND RESPONSE AFTER BIOLOGIC THERAPY INDUCTION PREDICTS ENDOSCOPIC REMISSION IN PEDIATRIC CROHNS DISEASE
BACKGROUND: Tumor necrosis factor inhibitors (TNFi) are a mainstay of pediatric Crohn’s disease (PCD) therapy; yet not all patients respond, and others lose response over time. Combination therapy with methotrexate may improve response; however, this has not been rigorously evaluated…
EARLY INTESTINAL ULTRASOUND RESPONSE TO BIOLOGIC AND SMALL MOLECULE THERAPY PREDICTS ENDOSCOPIC OUTCOMES IN CHILDREN WITH ULCERATIVE COLITIS
INTRODUCTION: Stride-II recommends early biomarker targets for treatment optimization to achieve treat-to-target (T2T) endoscopic remission (ER) in ulcerative colitis (UC). Predictive capabilities of intestinal ultrasound (IUS) for T2T ER remains unknown…
CHANGES IN THERAPY ARE NOT ASSOCIATED WITH INCREASED REMISSION IN PATIENTS WITH CROHN’S DISEASE OF THE POUCH
BACKGROUND: Prevention of postoperative recurrence (POR) in Crohn’s disease (CD) after ileo-colonic (IC) resection is still a highly debated topic. Prophylactic immunosuppression after surgery is currently recommended in presence of at least one clinical risk factor (RF)…
